JP7281470B2 - C5a受容体調節剤 - Google Patents

C5a受容体調節剤 Download PDF

Info

Publication number
JP7281470B2
JP7281470B2 JP2020539797A JP2020539797A JP7281470B2 JP 7281470 B2 JP7281470 B2 JP 7281470B2 JP 2020539797 A JP2020539797 A JP 2020539797A JP 2020539797 A JP2020539797 A JP 2020539797A JP 7281470 B2 JP7281470 B2 JP 7281470B2
Authority
JP
Japan
Prior art keywords
phenyl
dihydro
benzyl
methyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020539797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511327A5 (cg-RX-API-DMAC7.html
JP2021511327A (ja
Inventor
フロワドゥヴォー シルヴィ
ウブラー フランシス
マーフィー マーク
レンネベルグ ドルテ
シュタム ジモン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of JP2021511327A publication Critical patent/JP2021511327A/ja
Publication of JP2021511327A5 publication Critical patent/JP2021511327A5/ja
Application granted granted Critical
Publication of JP7281470B2 publication Critical patent/JP7281470B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020539797A 2018-01-19 2019-01-18 C5a受容体調節剤 Active JP7281470B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2018051283 2018-01-19
EPPCT/EP2018/051283 2018-01-19
PCT/EP2019/051245 WO2019141808A1 (en) 2018-01-19 2019-01-18 C5a receptor modulators

Publications (3)

Publication Number Publication Date
JP2021511327A JP2021511327A (ja) 2021-05-06
JP2021511327A5 JP2021511327A5 (cg-RX-API-DMAC7.html) 2022-01-21
JP7281470B2 true JP7281470B2 (ja) 2023-05-25

Family

ID=65023915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020539797A Active JP7281470B2 (ja) 2018-01-19 2019-01-18 C5a受容体調節剤

Country Status (6)

Country Link
US (1) US11685729B2 (cg-RX-API-DMAC7.html)
EP (1) EP3740477A1 (cg-RX-API-DMAC7.html)
JP (1) JP7281470B2 (cg-RX-API-DMAC7.html)
CN (1) CN111683937A (cg-RX-API-DMAC7.html)
CA (1) CA3087784A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019141808A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA124694C2 (uk) 2018-01-10 2021-10-27 Ідорсія Фармасьютікалз Лтд 2,4,6,7-ТЕТРАГІДРОПІРАЗОЛО[4,3-d]ПІРИМІДИН-5-ОНОВІ ПОХІДНІ ТА СПОРІДНЕНІ СПОЛУКИ ЯК МОДУЛЯТОРИ РЕЦЕПТОРА C5A ДЛЯ ЛІКУВАННЯ ВАСКУЛІТУ ТА ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ
WO2019141803A1 (en) 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
US11685729B2 (en) 2018-01-19 2023-06-27 Idorsia Pharmaceuticals Ltd. C5a receptor modulators

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023436A1 (en) 1998-10-16 2000-04-27 Sumitomo Pharmaceuticals Co., Ltd. Quinazolinone derivatives
JP2002528455A (ja) 1998-10-23 2002-09-03 エフ.ホフマン−ラ ロシュ アーゲー 二環式窒素複素環化合物
WO2008011032A1 (en) 2006-07-17 2008-01-24 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
JP2014511898A (ja) 2011-04-21 2014-05-19 アステックス、セラピューティックス、リミテッド 二環式複素環化合物および治療法におけるその使用
JP2021510373A (ja) 2018-01-10 2021-04-22 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd 血管炎及び炎症性疾患を治療するためのc5a受容体調節剤としての2,4,6,7−テトラヒドロ−ピラゾロ[4,3−d]ピリミジン−5−オン誘導体及び関連化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2118117A1 (en) 1993-02-18 1994-08-19 Shigeki Fujiwara Adenosine uptake inhibitor
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7476665B2 (en) 2003-06-26 2009-01-13 Merck & Co., Inc. Benzodiazepine CGRP receptor antagonists
WO2005019188A1 (ja) 2003-08-22 2005-03-03 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
JP2007515458A (ja) 2003-12-23 2007-06-14 テイボテク・フアーマシユーチカルズ・リミテツド Hivプロテアーゼ阻害剤の自己ミクロ乳化性薬剤送達システム
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
WO2007028789A1 (en) 2005-09-07 2007-03-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Quinazoline derivatives as antiviral agents
US7834000B2 (en) 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
EP2027106A2 (en) 2006-06-13 2009-02-25 Vertex Pharmaceuticals Incorporated Cgrp receptor antagonists
SA08280783B1 (ar) 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
DK2585064T3 (en) * 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
US20120143725A1 (en) 2010-12-02 2012-06-07 Vinimaya Inc. Methods and systems for influencing search and shopping decisions in electronic procurement
MX2016002544A (es) 2013-09-04 2016-06-17 Squibb Bristol Myers Co Compuestos utiles como inmunomoduladores.
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
CN114984016A (zh) * 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
WO2019141803A1 (en) 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
US11685729B2 (en) 2018-01-19 2023-06-27 Idorsia Pharmaceuticals Ltd. C5a receptor modulators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023436A1 (en) 1998-10-16 2000-04-27 Sumitomo Pharmaceuticals Co., Ltd. Quinazolinone derivatives
JP2002528455A (ja) 1998-10-23 2002-09-03 エフ.ホフマン−ラ ロシュ アーゲー 二環式窒素複素環化合物
WO2008011032A1 (en) 2006-07-17 2008-01-24 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
JP2014511898A (ja) 2011-04-21 2014-05-19 アステックス、セラピューティックス、リミテッド 二環式複素環化合物および治療法におけるその使用
JP2021510373A (ja) 2018-01-10 2021-04-22 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd 血管炎及び炎症性疾患を治療するためのc5a受容体調節剤としての2,4,6,7−テトラヒドロ−ピラゾロ[4,3−d]ピリミジン−5−オン誘導体及び関連化合物

Also Published As

Publication number Publication date
CA3087784A1 (en) 2019-07-25
CN111683937A (zh) 2020-09-18
US20210122736A1 (en) 2021-04-29
WO2019141808A1 (en) 2019-07-25
JP2021511327A (ja) 2021-05-06
EP3740477A1 (en) 2020-11-25
US11685729B2 (en) 2023-06-27

Similar Documents

Publication Publication Date Title
JP7281469B2 (ja) C5a受容体調節剤
JP7014914B2 (ja) 血管炎及び炎症性疾患を治療するためのc5a受容体調節剤としての2,4,6,7-テトラヒドロ-ピラゾロ[4,3-d]ピリミジン-5-オン誘導体及び関連化合物
JP2021511327A (ja) C5a受容体調節剤
EP4423082A1 (en) Ccr6 receptor modulators
AU2022374959A1 (en) Ccr6 receptor modulators
BR112020013788B1 (pt) Composto, composição farmacêutica, e, uso de um composto
HK40035648B (en) 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds for treating vasculitis and inflammatory diseases
HK40035648A (en) 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds for treating vasculitis and inflammatory diseases
EA042931B1 (ru) 2,4,6,7-ТЕТРАГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-5-ОНОВЫЕ ПРОИЗВОДНЫЕ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА C5A ДЛЯ ЛЕЧЕНИЯ ВАСКУЛИТА И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ
JP7820522B2 (ja) クラゾセンタン二ナトリウム塩、その製造及びそれを含有する医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221227

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230320

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230515

R150 Certificate of patent or registration of utility model

Ref document number: 7281470

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150